Answers are grounded in this paper and cite their sources.
Identifies 8-hydroxyquinolines that improve dopamine signaling in neurological conditions, suggesting new treatment pathways.
A series of 8-hydroxy quinolines were identified as potent inhibitors of catechol O-methyltransferase (COMT) with selectivity for the membrane-bound form of the enzyme. Small substituents at the 7-position of the quinoline were found to increase metabolic stability without sacrificing potency. Compounds with good pharmacokinetics and brain penetration were identified and demonstrated in vivo modulation of dopamine metabolites in the brain. An X-ray cocrystal structure of compound 21 in the S-COMT active site shows chelation of the active site magnesium similar to catechol-based inhibitors. These compounds should prove useful for treatment of many neurological and psychiatric conditions associated with compromised cortical dopamine signaling.
No takes yet. Share an insight, caveat, or question.
Buchler et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: